On 19 November 2014, orphan designation (EU/3/14/1361) was granted by the European Commission to Inventiva, France, for 1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid for the treatment of systemic sclerosis.
This medicine is now known as lanifibranor.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in November 2020 on request of the Sponsor.
1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid (lanifibranor)
|Disease / condition||
Treatment of systemic sclerosis
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.